Report Scope:
This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement, and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2019 and forecast for 2020-2025 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.
The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV, and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions, and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics, and others, are detailed with market data current and forecasts.
Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America, and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States, Europe, Japan, and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to our readers.
Report Includes:
- 33 data tables and 42 additional tables
- An overview of the global markets for treatment and diagnosis of sexually transmitted diseases
- Analyses of the global market trends, with corresponding market analysis data for 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of the impact of demographic, economic and other factors that will drive future demand for diagnostic and therapeutic interventions affecting sexually transmitted diseases market
- Estimation of market size and forecast the potential market for sexually transmitted disease therapeutics, along with global market share analysis on the basis of disease area and treatments, drug type, and geographical region
- Identification of unmet needs in sexually transmitted diseases therapeutics, promising new drugs and therapies still in the development and testing stage that will be commercialized successfully in the next five years
- Assessment of the long-term outlook for sexually transmitted diseases therapeutics, considering market opportunities as well as technological, financial and economic factors
- Insight into the factors driving and restraining the growth of the global market for treatment and diagnosis of sexually transmitted diseases, along with a regional market overviews for North America, Europe, Asia-Pacific, Latin America and the Middle East
- Company profiles of the leading drug manufacturers and suppliers, market including Abbott Laboratories, AbbVie Inc., Novartis AG, Pfizer Inc., and Thermo Fisher Scientific Inc.
Summary:
Sexually transmitted infections can be asymptomatic and often go undiagnosed. Routine screening and preventive measures are important for early identification, which can prevent severe complications and further transmission. An untreated STD can result in several other chronic diseases or conditions including pelvic inflammatory disease (PID), infertility, and increased risk of HIV and other STDs. There are certain strains of HPV that are linked to cervical, penile, throat, and anal cancers. Various types of STDs include -
- Gonorrhea.
- Syphilis.
- Herpes.
- Chlamydia.
- Hepatitis (HBV).
- Human Immunodeficiency Virus (HIV).
- Human Papillomavirus (HPV or genital warts).
- Chancroid.
- Trichomoniasis.
Sexually transmitted infections are spread through sexual contact. These infections are primarily transmitted from one person to another via sexually transmissible bacteria, viruses and parasites. There are several STDs that can be transmitted through tissue transfer, blood products and from mother to child during childbirth or pregnancy. The disease symptoms vary from one person to another; in a few cases there might be no disease symptoms. Symptoms can be mild or acute from one individual to another. There can be severe consequences or long-term complications in individuals suffering from a sexually transmitted disease.
A significant proportion of sexually transmitted diseases worldwide is caused by seven major infections: syphilis, chlamydia, gonorrhea, genital herpes, hepatitis B, human papillomavirus (HPV), and trichomoniasis. These diseases have a high prevalence, particularly in developing countries, and it can result in substantial productivity losses for individuals and communities. In developing countries, sexually transmitted infections are among the leading causes of disability.
Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Global Market Overview and Trends
Overview of Sexually Transmitted Diseases and Definitions
Sexually Transmitted Diseases and Pregnancy
Screening Programs and Guidelines
Mobile HIV Testing in Brazil
Benzathine Penicillin Drug Shortage
Trends in the Global Transmission of STDs
Increasing Incidence of STDs
STD Awareness and Screening Services
Development of Test Kits with High Sensitivity for Low Resource Settings
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
Rising Incidence of Antibiotic Resistance
Lack of Prenatal Screening for STDs
Chapter 4 Disease Overview
Introduction
Chlamydia
Overview
Epidemiology
Diagnosis
Treatments
Genital Herpes
Overview
Epidemiology
Diagnosis
Treatments
Gonorrhea
Overview
Epidemiology
Treatments
Hepatitis A, B and C
Overview
Epidemiology
Diagnosis
Treatments
Market Size
HIV/AIDS
Overview
Epidemiology
Diagnosis
Treatments
Market Size and Forecast
HPV
Overview
Diagnosis
Treatments
Syphilis
Overview
Epidemiology
Diagnosis
Treatments
Others
Overview
Market Analysis
Chapter 5 STD Diagnosis and Treatment Options
Introduction to STD Diagnostics by Test Type
Enzyme Immunoassay (EIA) and ELISA
Polymerase Chain Reaction (PCR)
Rapid Diagnostics Tests (RDTs)
Others
Introduction to Treatment by Drug Class
Antibiotics/Antibacterial
Antiviral/ Antiretrovirals
Others
Chapter 6 North American Market
North American Market
United States
Canada
Mexico
Chapter 7 European Market
European Market
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
Chapter 8 Asia-Pacific Market
Introduction
Key Trends in STI Prevention
Asia-Pacific Market
China
Japan
India
South Korea
Rest of Asia-Pacific
Chapter 9 Rest of the World Market
Rest of the World Market
Chapter 10 Regulatory Structure
Overview of Regulations
United States
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
Chapter 11 Company Profiles
ABBOTT LABORATORIES
ABBVIE INC.
AGILENT TECHNOLOGIES INC.
BECTON, DICKINSON AND CO.
BIOMERIEUX INC.
BIO-RAD LABORATORIES INC.
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
BRISTOL-MYERS SQUIBB CO.
CEPHEID INC.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
HOFFMANN-LA ROCHE INC.
HOLOGIC INC.
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
PROMEGA CORP.
QIAGEN N.V.
QUIDEL CORP.
THERMO FISHER SCIENTIFIC INC.
Chapter 12 Appendix
Acronyms
List of Tables
Table A : Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2025
Table B : Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2025
Table 1 : Sexually Transmitted Diseases, by Different Pathogens
Table 2 : Global Market for STD Therapeutics, by Disease Area, Through 2025
Table 3 : Incidence of Chlamydia, by Country, 2012-2018
Table 4 : Chlamydia Diagnostic Products, by Brand Name and Manufacturer
Table 5 : Drugs for Chlamydia Treatment
Table 6 : Global HSV-1 Prevalence Cases, Aged 0-49 years, by Region, 2016
Table 7 : Global HSV-1 Prevalence, Aged 0-49 years, by Region, 2016
Table 8 : Genital Herpes Diagnostic Products, by Brand Name and Manufacturer
Table 9 : Epidemiology of Gonorrhea, by Country, 2012-2018
Table 10 : Gonorrhea Diagnostic Products, by Brand Name and Manufacturer
Table 11 : Drug for Gonorrhea Treatment
Table 12 : Incidence of Hepatitis A, by Country, 2012-2017
Table 13 : Incidence of Hepatitis B, by Country, 2012-2017
Table 14 : Incidence of Hepatitis C, by Country, 2012-2015
Table 15 : Hepatitis B and C Diagnostic Products, by Brand Name and Manufacturer
Table 16 : Hepatitis B Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 17 : Hepatitis C Medications, by Brand Name, Generic Name, Manufacturer, and Indication
Table 18 : Global Market for Hepatitis Therapeutics, by Region, Through 2025
Table 19 : HIV Prognosis
Table 20 : Snapshot of Global HIV Epidemic, by Region, 2019
Table 21 : HIV/AIDS Diagnostic Products, by Brand Name and Manufacturer
Table 22 : HIV Medications, by Drug Class, Generic Name, and Brand Name
Table 23 : Global Market for HIV/AIDS Therapeutics, by Region, Through 2025
Table 24 : HPV Diagnostic Products, by Brand Name and Manufacturer
Table 25 : HPV Vaccines
Table 26 : Incidence of Syphilis, by Country, 2013-2018
Table 27 : Syphilis Diagnostic Products, by Brand Name and Manufacturer
Table 28 : Drug for Syphilis Treatment
Table 29 : Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type, and Manufacturer
Table 30 : Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 31 : Global Market for Other Therapeutics, by Region, Through 2025
Table 32 : Global Market for STD Diagnostics, by Region, Through 2025
Table 33 : Global Market for STD Diagnostics, by Test Type, Through 2025
Table 34 : Antibacterial Drugs for Treatment of STDs
Table 35 : Global Market for Antibiotics, by Region, Through 2025
Table 36 : Global Market for Antiviral/Antiretroviral Drugs, by Region, Through 2025
Table 37 : Global Market for Other Drug Classes, by Region, Through 2025
Table 38 : North American HBsAG Seroprevalence, by Country, 2016
Table 39 : North American Market for STD Therapeutics, by Disease Area, Through 2025
Table 40 : North American Market for STD Therapeutics, by Drug Class, Through 2025
Table 41 : U.S. Historic and Current Chancroid Trends and Incidence, 1990-2018
Table 42 : European Market for STD Therapeutics, by Disease Area, Through 2025
Table 43 : European Market for STD Therapeutics, by Drug Class, Through 2025
Table 44 : Asia-Pacific Market for STD Therapeutics, by Disease Area, Through 2025
Table 45 : Asia-Pacific Market for STD Therapeutics, by Drug Class, Through 2025
Table 46 : South American, Middle Eastern and African HIV/AIDS Epidemiology, 2019
Table 47 : South American, Middle Eastern and African Market for STD Therapeutics, by Disease Area, Through 2025
Table 48 : South American, Middle Eastern and African Market for STD Therapeutics, by Drug Class, Through 2025
Table 49 : Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 50 : Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 51 : Abbott Laboratories: Marketed Products
Table 52 : Abbott Laboratories: Marketed Products, Diagnostics
Table 53 : Abbott Laboratories: Financials, 2017-2019
Table 54 : AbbVie Inc.: Marketed Products
Table 55 : AbbVie Inc.: Financials, 2017-2019
Table 56 : Agilent Technologies Inc.: Financials, 2017-2019
Table 57 : Becton, Dickinson and Co.: Marketed Products
Table 58 : Biomerieux Inc.: Marketed Products
Table 59 : Bio-Rad Laboratories: Marketed Products
Table 60 : Bristol-Myers Squibb Co.: Marketed Products
Table 61 : Bristol-Myers Squibb Company: Financials, 2017-2019
Table 62 : Gilead Sciences Inc.: Marketed Products
Table 63 : GlaxoSmithKline plc: Marketed Products
Table 64 : ViiV Healthcare Group of Companies: Marketed Products
Table 65 : Hoffmann-La Roche Inc.: Marketed Products
Table 66 : Hologic Inc.: Marketed Products
Table 67 : Hologic Inc.: Financials, 2017-2019
Table 68 : Merck & Co. Inc.: Marketed Products
Table 69 : Novartis AG: Marketed Products
Table 70 : Pfizer Inc.: Marketed Products, by Indication
Table 71 : Qiagen N.V.: Marketed Products
Table 72 : Quidel Corp.: Marketed Products
Table 73 : Thermo Fisher Scientific Inc.: Marketed Products
Table 74 : Acronyms Used in the Sexually Transmitted Disease Therapeutics and Diagnostics Market
List of Figures
Figure A : Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2019-2025
Figure B : Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2019-2025
Figure 1 : Death Share Due to Infectious and Parasitic Diseases, 2016
Figure 2 : Incidence of Gonorrhea, by Country, 2015-2018
Figure 3 : U.S. Funding Trends, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2019
Figure 4 : Global Market for STD Therapeutics, 2019-2025
Figure 5 : Global Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 6 : Global Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 7 : Global Historic and Current Chlamydia Trend and Incidence in Women, by Country, 2016-2018
Figure 8 : Global Incidence of Gonorrhea in Men, by Country, 2015-2017
Figure 9 : Hepatitis Timeline, 1990-2004
Figure 10 : Hepatitis Timeline, 2011-2015
Figure 11 : Hepatitis Timeline, 2015-2017
Figure 12 : Global Market for Hepatitis Therapeutics, 2019-2025
Figure 13 : Global Market for Hepatitis Therapeutics, by Region, 2019-2025
Figure 14 : Global Market for HIV/AIDS Therapeutics, 2019-2025
Figure 15 : Global Market for HIV/AIDS Therapeutics, by Region, 2019-2025
Figure 16 : U.S. Incidence of Syphilis Among Newborns, 2016-2018
Figure 17 : Global Market for Other Therapeutics, 2019-2025
Figure 18 : Global Market for Other Therapeutics, by Region, 2019-2025
Figure 19 : Global Market for STD Diagnostics, 2019-2025
Figure 20 : Global Market for STD Diagnostics, by Region, 2019-2025
Figure 21 : Global Market Shares of STD Diagnostics, by Test Type, 2019
Figure 22 : Global Market Shares of STD Diagnostics, by Test Type, 2025
Figure 23 : Global Market for EIA and ELISA Diagnostics, 2019-2025
Figure 24 : Global Market for PCR Diagnostics, 2019-2025
Figure 25 : Global Market for RDT Diagnostics, 2019-2025
Figure 26 : Global Market for Other Diagnostics, 2019-2025
Figure 27 : Global Market for Antibiotic Drugs, 2019-2025
Figure 28 : Global Market for Antibiotic Drugs, by Region, 2019-2025
Figure 29 : Global Market for Antiviral/Antiretroviral Drugs, 2019-2025
Figure 30 : Global Market for Antiviral/Antiretroviral Drugs, by Region, 2019-2025
Figure 31 : Global Market for Other Drug Classes, 2019-2025
Figure 32 : Global Market for Other Drug Classes, by Region, 2019-2025
Figure 33 : North American Market for STD Therapeutics, 2019-2025
Figure 34 : North American Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 35 : North American Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 36 : North American Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 37 : North American Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 38 : North American Market for STD Therapeutics, by Country, 2019-2025
Figure 39 : U.S. Incidence of STDs, 2018
Figure 40 : U.S. Sexually Transmitted Infections, by Sex, 2018
Figure 41 : U.S. Historic and Current Syphilis Trends and Incidence, 2000-2018
Figure 42 : U.S. Historic and Current Chlamydia Trends and Incidence, 2000-2018
Figure 43 : U.S. Historic and Current Gonorrhea Trends and Incidence, 2000-2018
Figure 44 : U.S. Historic and Current Hepatitis A Trends and Incidence, 2013-2018
Figure 45 : U.S. Historic and Current Acute Hepatitis B Trends and Incidence, 2013-2018
Figure 46 : U.S. Historic and Current Hepatitis C Trends and Incidence, 2013-2018
Figure 47 : U.S. Historic and Current HIV Trends and Incidence, 2011-2018
Figure 48 : U.S. Market for STD Therapeutics, 2019-2025
Figure 49 : Canadian Sexually Transmitted Infections, by Sex, 2018
Figure 50 : Canadian Historic and Current Chlamydia Trends and Incidence, 2008-2018
Figure 51 : Canadian Historic and Current Gonorrhea Trends and Incidence, by Sex, 2008-2018
Figure 52 : Canadian Historic and Current Infectious Syphilis Trends and Incidence, 2008-2018
Figure 53 : Canadian Historic and Current Congenital Syphilis Trends and Incidence, 2008-2018
Figure 54 : Canadian Market for STD Therapeutics, 2019-2025
Figure 55 : Mexican Market for STD Therapeutics, 2019-2025
Figure 56 : European Historic and Current Chlamydia Trends and Incidence, by Country, 2014-2018
Figure 57 : European Historic and Current AIDS Trends and Incidence, by Country, 2014-2018
Figure 58 : European Market for STD Therapeutics, 2019-2025
Figure 59 : European Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 60 : European Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 61 : European Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 62 : European Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 63 : European Market for STD Therapeutics, by Country, 2019-2025
Figure 64 : U.K. Incidence of HIV among Gay and Bisexual Men, 2015-2018
Figure 65 : U.K. Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 66 : U.K. Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 67 : U.K. Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 68 : U.K. Market for STD Therapeutics, 2019-2025
Figure 69 : German Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 70 : German Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 71 : German Market for STD Therapeutics, 2019-2025
Figure 72 : French Historic and Current Chlamydia Trends and Incidence, 2012-2017
Figure 73 : French Historic and Current Gonorrhea Trends and Incidence, 2014-2018
Figure 74 : French Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 75 : French Market for STD Therapeutics, 2019-2025
Figure 76 : Spanish Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 77 : Spanish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 78 : European Centre for Disease Prevention and Control: Annual Epidemiological Report
Figure 79 : Spanish Market for STD Therapeutics, 2019-2025
Figure 80 : Italian Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 81 : Italian Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 82 : Italian Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 83 : Italian Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 84 : Italian Market for STD Therapeutics, 2019-2025
Figure 85 : Denmark's Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 86 : The Netherlands Historic and Current Chlamydia Trends and Incidence, 2012-2018
Figure 87 : Denmark's Historic and Current Gonorrhea Trends and Incidence, 2011-2018
Figure 88 : Irish Historic and Current Gonorrhea Trends and Incidence, 2012-2018
Figure 89 : The Netherlands Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 90 : Swedish Historic and Current Hepatitis B Trends and Incidence, 2012-2018
Figure 91 : Swedish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 92 : Polish Historic and Current Hepatitis C Trends and Incidence, 2012-2018
Figure 93 : Rest of European Market for STD Therapeutics, 2019-2025
Figure 94 : Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 95 : Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2019
Figure 96 : Asia-Pacific Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 97 : Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 98 : Asia-Pacific Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 99 : Asia-Pacific Market for STD Therapeutics, by Country, 2019-2025
Figure 100 : Chinese Market for STD Therapeutics, 2019-2025
Figure 101 : Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2017
Figure 102 : Japanese Market for STD Therapeutics, 2019-2025
Figure 103 : Indian Historic and Current HIV Trends and Incidence, 2005-2018
Figure 104 : Indian Historic and Current HIV Trends and Prevalence, 2005-2018
Figure 105 : Indian Historic and Current AIDS Mortality, 2005-2018
Figure 106 : Indian Market for STD Therapeutics, 2019-2025
Figure 107 : South Korean Historic and Current HIV/AIDS Infections and Incidence, 2001-2018
Figure 108 : South Korean Market for STD Therapeutics, 2019-2025
Figure 109 : Rest of Asia-Pacific Market for STD Therapeutics, 2019-2025
Figure 110 : South American, Middle Eastern and African Market for STD Therapeutics, 2019-2025
Figure 111 : South American, Middle Eastern and African Market Shares of STD Therapeutics, by Disease Area, 2025
Figure 112 : South American, Middle Eastern and Africa Market Shares of STD Therapeutics, by Drug Class, 2019
Figure 113 : South American, Middle Eastern and African Market Shares of STD Therapeutics, by Drug Class, 2025
Figure 114 : Abbott Laboratories: Revenue Share, by Region, 2019
Figure 115 : Abbott Laboratories: Revenue Share, by Business Segment, 2019
Figure 116 : AbbVie Inc.: Revenue Share, by Country, 2019
Figure 117 : Agilent Technologies Inc.: Revenue Share, by Region, 2019
Figure 118 : Agilent Technologies Inc.: Revenue Share, by Business Segment, 2019
Figure 119 : Becton, Dickinson and Co.: Financial Performance, 2013-2019
Figure 120 : Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2019
Figure 121 : Becton, Dickinson and Co.: Revenue Share, by Region, 2019
Global Sexually Transmitted Diseases Testing Professional Survey Report 2023, Forecast to 2028
Published: 22-Dec-2023 Price: US 3280 Onwards Pages: 106
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.
D......
Global Sexually Transmitted Diseases Testing Market Research Report 2023, Forecast to 2028
Published: 22-Dec-2023 Price: US 2680 Onwards Pages: 130
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.
D......
Global Sexually Transmitted Disease (STD) Testing Market Status and Outlook 2023-2028
Published: 23-Nov-2023 Price: US 3160 Onwards Pages: 102
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period.
D......
Global Sexually Transmitted Disease (Std) Testing Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 05-Oct-2023 Price: US 3380 Onwards Pages: 100
Market Overview of Global Sexually Transmitted Disease (Std) Testing market:
According to our latest research, the global Sexually Transmitted Disease (Std) Testing market looks promising in the next 5 years. As of 2022, the global Sexually Transmitted Disease (Std) Testing market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and pr......
Global Gonorrhea Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 05-Oct-2023 Price: US 3380 Onwards Pages: 98
Market Overview of Global Gonorrhea Therapeutics market:
According to our latest research, the global Gonorrhea Therapeutics market looks promising in the next 5 years. As of 2022, the global Gonorrhea Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Gonorrhea is a sexually transmitted disease (STD) caused by the bacterium Neisseria gonorrhea. It tends to infect the urethra......
Global Gonorrhea Therapeutics Market Insights, Forecast to 2029
Published: 14-Aug-2023 Price: US 4900 Onwards Pages: 89
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospec......
Global Sexually Transmitted Disease (STD) Testing Market Insights, Forecast to 2029
Published: 01-Jun-2023 Price: US 4900 Onwards Pages: 92
Sexually Transmitted Disease (STD) Testing is a medical means of testing, prevention, and treatment of Sexually Transmitted Disease (STD).
Market Analysis and Insights: Global Sexually Transmitted Disease (STD) Testing Market
The global Sexually Transmitted Disease (STD) Testing market is projected to grow from US$ 225.3 million in 2023 to US$ 338.1 million by 2029, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period.
The need for tests that eliminate ......
Global Sexually Transmitted Disease (STD) Testing Market Research Report 2023
Published: 05-May-2023 Price: US 2900 Onwards Pages: 89
Sexually Transmitted Disease (STD) Testing is a medical means of testing, prevention, and treatment of Sexually Transmitted Disease (STD).
Highlights
The global Sexually Transmitted Disease (STD) Testing market was valued at US$ 225.3 million in 2022 and is anticipated to reach US$ 338.1 million by 2029, witnessing a CAGR of 7.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The need ......
Global Gonorrhea Therapeutics Market Status and Outlook 2023-2028
Published: 24-Apr-2023 Price: US 3160 Onwards Pages: 104
Neisseria gonorrhoeae infection can manifest as a variety of symptoms, which can affect the genitourinary system, anorectum, pharynx, and conjunctival area. Severe cases can lead to disseminated gonococcal infection, endocarditis and meningitis; in women, it is pelvic inflammatory disease (PID).
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
